Analysis of residual tumor cells revealed persistent CD155 expression (Supplemental Figure 5G), suggesting that relapse was not due to antigen loss but rather to limited CAR-T cell persistence and/or insufficient dosing. This evidence concerns the gene PVR and neoplasm.